A5057899912- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Biosimilars and Bioanalytical Methods
- Helicobacter pylori-related gastroenterology studies
- Diverticular Disease and Complications
- Chronic Lymphocytic Leukemia Research
- Liver Diseases and Immunity
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders Research
- Diagnosis and treatment of tuberculosis
- Systemic Lupus Erythematosus Research
- Colorectal Cancer Treatments and Studies
- Pharmaceutical studies and practices
- Anorectal Disease Treatments and Outcomes
- Appendicitis Diagnosis and Management
- Gastrointestinal Tumor Research and Treatment
- Acute Lymphoblastic Leukemia research
- Health Systems, Economic Evaluations, Quality of Life
- Gastric Cancer Management and Outcomes
- Mycobacterium research and diagnosis
- Pregnancy and Medication Impact
- Colorectal Cancer Screening and Detection
University of Amsterdam
2016-2025
Amsterdam University Medical Centers
2018-2025
Icahn School of Medicine at Mount Sinai
2020-2025
Amsterdam UMC Location University of Amsterdam
2015-2024
KU Leuven
2003-2024
University Medical Center
2019-2024
University of Calgary
2007-2024
Inserm
2024
McGill University Health Centre
2024
St. Thomas Hospital
2023
We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer sought associations between mutation status KRAS gene in tumors clinical response to cetuximab.We randomly assigned patients with epidermal growth factor receptor-positive unresectable metastases receive FOLFIRI either alone or combination cetuximab. The primary end point was progression-free survival.A total 599 received FOLFIRI, alone....
The comparative efficacy and safety of infliximab azathioprine therapy alone or in combination for Crohn's disease are unknown.
Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the of tofacitinib and maintenance therapy.
Crohn's disease is a heterogeneous entity. Previous attempts of classification have been based primarily on anatomic location and behavior disease. However, no uniform definition patient subgroups has yet achieved broad acceptance. The aim this international Working Party was to develop simple objective variables. Eight outcome-related variables relevant were identified stepwise evaluated in 413 consecutive cases, database survey, by clinical considerations. Allocation conducted with...
Background: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF infliximab. No anti-TNF agent has been evaluated prospectively in had responded another and then lost that response or were intolerant of agent. Objective: To determine whether adalimumab induces remissions more frequently than placebo adult have symptoms despite infliximab therapy cannot take because adverse events. Design:...
Principal changes with respect to the 2004 ECCO guidelines Ileocolonoscopy is recommended within first year after surgery where treatment decisions may be affected (Statement 8C). Thiopurines are more effective than mesalazine or imidazole antibiotics alone in post-operative prophylaxis 8F). ### 8.1 Epidemiology of Crohn's disease In natural history CD, intestinal resection almost unavoidable since about 80% patients require at some stage. Surgery unfortunately not curative as disease...
Fecal calprotectin is a marker of inflammation in inflammatory bowel disease (IBD). Since mucosal healing has become goal treatment IBD we examined how reliably levels reflect activity. In all, 126 patients and 32 irritable syndrome (IBS) needing colonoscopy delivered sample feces prior to the start cleansing. Besides collection symptom scores blood tests, experienced endoscopists recorded Simple Endoscopic Score for Crohn's Disease (SES-CD) Index Severity (CDEIS) (CD) Mayo endoscopic score...
<h3>Objective</h3> Vedolizumab is a gut-selective antibody to α<sub>4</sub>β<sub>7</sub> integrin for the treatment of ulcerative colitis (UC) and Crohn9s disease (CD). We report an integrated summary safety vedolizumab. <h3>Design</h3> Safety data (May 2009–June 2013) from six trials vedolizumab were integrated. Adverse events evaluated in patients who received ≥1 dose or placebo reported as exposure-adjusted incidence rates number experiencing event per 100 person-years (PYs) exposure....
Background & AimsThere is an increasing need for new treatments patients with Crohn's disease (CD) in whom previous therapy tumor necrosis factor (TNF) antagonists has failed. We performed a placebo-controlled, phase 3, double-blind trial to evaluate the efficacy and safety of vedolizumab, antibody against integrin α4β7, as induction therapy.MethodsPatients moderately severely active CD (CD activity index [CDAI] score, 220–400 points) were assigned randomly groups given vedolizumab (300 mg)...
Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in majority patients, which can lead infusion reactions and a shorter duration response. Concomitant use immunosuppressives (IS) reduces risk ATI formation.To investigate IS-that is, methotrexate (MTX) or azathioprine (AZA)-is most effective at reducing formation, multicentre cohort 174 patients Crohn's disease, treated an on-demand schedule, was prospectively studied. Three groups were studied:...
### 5.1 General The general principles for treating active ulcerative colitis are to consider the activity, distribution (proctitis, left-sided, extensive,1 and pattern of disease (relapse frequency, course disease, response previous medications, side-effect profile medication, extra-intestinal manifestation), before treatment decisions made in conjunction with patient. #### 5.1.1 Disease activity The principal scoring systems used clinical trials covered Section 5.1.2 have been...
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure activity at specific point in time. An instrument to cumulative structural damage the bowel, which may predict long-term disability, needed. The aim of this article outline methods develop an that can bowel damage. project being conducted by International Program New Indexes (IPNIC) group. This instrument, called Disease Digestive Damage Score (the Lémann score), should take into...